Research advances in metabolomics in nonalcoholic fatty liver disease

Yuting LUAN; Zhongming HUANG; Wenjuan SHEN; Minghao HA; Zhibing XU

doi:10.3969/j.issn.1001-5256.2021.04.047

Volume 37 Issue 4

Apr. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(4): 943-946

PDF( 1902 KB)

Research advances in metabolomics in nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.04.047

Department of Infectious Diseases, The Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China

Received Date: 2020-11-06
Accepted Date: 2020-12-17
Published Date: 2021-04-20

Abstract

Abstract

The incidence rate of nonalcoholic fatty liver disease (NAFLD) is gradually increasing, and NAFLD has become the most important chronic liver disease in China. At present, the pathogenesis of NAFLD has not been fully elucidated and there are still no effective drugs. From the perspectives of pathogenesis, noninvasive diagnosis, and drug action and efficacy, this article introduces the research advances in metabolomics regarding endogenous small molecule metabolites in NAFLD, so as to provide new ideas and methods for further exploration of NAFLD.
- Non-alcoholic Fatty Liver Disease,
- Metabolomics,
- Diagnosis

FullText(HTML)

志谢: 感谢所有参与本研究的患者及其家人的理解和支持，感谢姬旭慧、刘媛、谢霄梦等参与采集样本及随访的研究生同学。

References(38)

References

[1]	DIEHL AM, DAY C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med, 2017, 377(21): 2063-2072. DOI: 10.1056/NEJMra1503519.
[2]	YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
[3]	LI J, ZOU B, YEO YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398. DOI: 10.1016/S2468-1253(19)30039-1.
[4]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10. 3969/j. issn.1001-5256.2018.05.007 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007
[5]	ESTES C, RAZAVI H, LOOMBA R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease[J]. Hepatology, 2018, 67(1): 123-133. DOI: 10.1002/hep.29466.
[6]	ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
[7]	ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312.
[8]	XUE R, FAN JG. Brief introduction of an international expert consensus statement: A new definition of metabolic associated fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007. 薛芮, 范建高. 代谢相关脂肪性肝病新定义的国际专家共识简介[J]. 临床肝胆病杂志, 2020, 36(6): 1224-1227. DOI: 10.3969/j.issn.1001-5256.2020.06.007.
[9]	NICHOLSON JK, LINDON JC, HOLMES E. 'Metabonomics': Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data[J]. Xenobiotica, 1999, 29(11): 1181-1189. DOI: 10.1080/004982599238047.
[10]	XU TR, LIU XY, XU GW. Advances of analytical methods for liquid chromatography-mass spectrometry-based metabolomics[J]. J Instrumental Analysis, 2020, 39(1): 10-18. DOI: 10.3969/j.issn.1004-4957.2020.01.002. 徐天润, 刘心昱, 许国旺. 基于液相色谱-质谱联用技术的代谢组学分析方法研究进展[J]. 分析测试学报, 2020, 39(1): 10-18. DOI: 10.3969/j.issn.1004-4957.2020.01.002.
[11]	NASCIMBENI F, PAIS R, BELLENTANI S, et al. From NAFLD in clinical practice to answers from guidelines[J]. J Hepatol, 2013, 59(4): 859-871. DOI: 10.1016/j.jhep.2013.05.044.
[12]	DAY CP, JAMES OF. Steatohepatitis: A tale of two "hits"?[J]. Gastroenterology, 1998, 114(4): 842-845. DOI: 10.1016/s0016-5085(98)70599-2.
[13]	TILG H, MOSCHEN AR. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis[J]. Hepatology, 2010, 52(5): 1836-1846. DOI: 10.1002/hep.24001.
[14]	TILG H, ADOLPH TE, MOSCHEN AR. Multiple parallel hits hypothesis in NAFLD - revisited after a decade[J]. Hepatology, 2021, 73(2): 833-842. DOI: 10.1002/hep.31518.
[15]	CABRÉ N, LUCIANO-MATEO F, BAIGES-GAYÀ G, et al. Plasma metabolic alterations in patients with severe obesity and non-alcoholic steatohepatitis[J]. Aliment Pharmacol Ther, 2020, 51(3): 374-387. DOI: 10.1111/apt.15606.
[16]	ZHONG G, KIRKWOOD J, WON KJ, et al. Characterization of vitamin A metabolome in human livers with and without nonalcoholic fatty liver disease[J]. J Pharmacol Exp Ther, 2019, 370(1): 92-103. DOI: 10.1124/jpet.119.258517.
[17]	SHIH LM, TANG HY, LYNN KS, et al. Stable isotope-labeled lipidomics to unravel the heterogeneous development lipotoxicity[J]. Molecules, 2018, 23(11): 2862. DOI: 10.3390/molecules23112862.
[18]	European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol, 2015, 63(1): 237-264. DOI: 10.1016/j.jhep.2015.04.006.
[19]	MARENGO A, JOUNESS RI, BUGIANESI E. Progression and natural history of nonalcoholic fatty liver disease in adults[J]. Clin Liver Dis, 2016, 20(2): 313-324. DOI: 10.1016/j.cld.2015.10.010.
[20]	ZENG J, FAN JG. Clinical significance of renaming nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2020, 36(6): 1205-1207. DOI: 10.3969/j.issn.1001-5256.2020.06.002. 曾静, 范建高. 非酒精性脂肪性肝病更名的临床意义[J]. 临床肝胆病杂志, 2020, 36(6): 1205-1207. DOI: 10.3969/j.issn.1001-5256.2020.06.002.
[21]	MOOLLA A, de BOER J, PAVLOV D, et al. Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome[J]. Aliment Pharmacol Ther, 2020, 51(11): 1188-1197. DOI: 10.1111/apt.15710.
[22]	MAYO R, CRESPO J, MARTÍNEZ-ARRANZ I, et al. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts[J]. Hepatol Commun, 2018, 2(7): 807-820. DOI: 10.1002/hep4.1188.
[23]	YANG RX, HU CX, SUN WL, et al. Serum monounsaturated triacylglycerol predicts steatohepatitis in patients with non-alcoholic fatty liver disease and chronic hepatitis B[J]. Sci Rep, 2017, 7(1): 10517. DOI: 10.1038/s41598-017-11278-x.
[24]	HU WY, MA XH, LI XX, et al. Progress of potential drugs in non-alcohol fatty liver disease[J]. Chin J New Drugs, 2017, 26(14): 1661-1666. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYZ201714009.htm 胡文义, 马晓慧, 李欣欣, 等. 非酒精性脂肪肝潜在药物研究进展[J]. 中国新药杂志, 2017, 26(14): 1661-1666. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYZ201714009.htm
[25]	DENG Y, PAN M, NIE H, et al. Lipidomic analysis of the protective effects of Shenling Baizhu San on non-alcoholic fatty liver disease in rats[J]. Molecules, 2019, 24(21): 3943. DOI: 10.3390/molecules24213943.
[26]	XU Y, HAN J, DONG J, et al. Metabolomics characterizes the effects and mechanisms of quercetin in nonalcoholic fatty liver disease development[J]. Int J Mol Sci, 2019, 20(5): 1220. DOI: 10.3390/ijms20051220.
[27]	KALAVALAPALLI S, BRIL F, GUINGAB J, et al. Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis[J]. J Endocrinol, 2019, 241(3): 293-305. DOI: 10.1530/JOE-19-0007.
[28]	TORQUATO P, GIUSEPPONI D, ALISI A, et al. Nutritional and lipidomics biomarkers of docosahexaenoic acid-based multivitamin therapy in pediatric NASH[J]. Sci Rep, 2019, 9(1): 2045. DOI: 10.1038/s41598-018-37209-y.
[29]	WU Y, LI L. Sample normalization methods in quantitative metabolomics[J]. J Chromatogr A, 2016, 1430: 80-95. DOI: 10.1016/j.chroma.2015.12.007.
[30]	YIN P, XU G. Current state-of-the-art of nontargeted metabolomics based on liquid chromatography-mass spectrometry with special emphasis in clinical applications[J]. J Chromatogr A, 2014, 1374: 1-13. DOI: 10.1016/j.chroma.2014.11.050.
[31]	GONZÁLEZ-DOMÍNGUEZ R, GONZÁLEZ-DOMÍNGUEZ Á, SAYAGO A, et al. Recommendations and best practices for standardizing the pre-analytical processing of blood and urine samples in metabolomics[J]. Metabolites, 2020, 10(6): 1220. DOI: 10.3390/metabo10060229.
[32]	MISRA BB. Data normalization strategies in metabolomics: Current challenges, approaches, and tools[J]. Eur J Mass Spectrom (Chichester), 2020, 26(3): 165-174. DOI: 10.1177/1469066720918446.
[33]	CHERNYAK OO, SENTSOVA TB, VOROZHKO IV, et al. Genomic, proteomic and metabolomic predictors of nonalcoholic fatty liver disease development in obese patients. Part I[J]. Vopr Pitan, 2015, 84(4): 18-24. http://europepmc.org/abstract/MED/26852528
[34]	MESNAGE R, RENNEY G, SÉRALINI GE, et al. Multiomics reveal non-alcoholic fatty liver disease in rats following chronic exposure to an ultra-low dose of Roundup herbicide[J]. Sci Rep, 2017, 7: 39328. DOI: 10.1038/srep39328.
[35]	DEL CHIERICO F, NOBILI V, VERNOCCHI P, et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach[J]. Hepatology, 2017, 65(2): 451-464. DOI: 10.1002/hep.28572.
[36]	CARULLI L, ZANCA G, SCHEPIS F, et al. The OMICs window into nonalcoholic fatty liver disease (NAFLD)[J]. Metabolites, 2019, 9(2): 25. DOI: 10.3390/metabo9020025.
[37]	PIAZZOLLA VA, MANGIA A. Noninvasive diagnosis of NAFLD and NASH[J]. Cells, 2020, 9(4): 1005. DOI: 10.3390/cells9041005.
[38]	ZHANG W, SHI JP. A new model for prevention and treatment of MAFLD to promote whole process stratification management[J]. J Prac Hepatol, 2020, 23(5): 609-611. DOI: 10.3969/j.issn.1672-5069.2020.05.001. 张伟, 施军平. 创建MAFLD防治新模式, 合力推进分层全程管理[J]. 实用肝脏病杂志, 2020, 23(5): 609-611. DOI: 10.3969/j.issn.1672-5069.2020.05.001.

Relative Articles

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	亢必勃，赵绒，赵杨，申焕君，陈朝霞，周云，范超. 血浆B细胞趋化因子1和干细胞因子水平与HBV感染患者临床指标的关系. 基础医学与临床. 2023(02): 289-292 .
2.	付雪，宁登，陈劲，杜鹏程，刘秋梦，姜立. eEF1A1通过HGF/c-MET通路调控肝癌细胞的迁移和侵袭能力. 中国组织化学与细胞化学杂志. 2023(02): 119-127 .
3.	赵晨晨，杨方，王伟. 干扰素联合肝动脉化疗栓塞和门静脉化疗对预防肝癌术后复发的临床意义分析. 中国现代药物应用. 2022(03): 150-152 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (966) PDF downloads(159)

Research advances in metabolomics in nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2021.04.047